NODÜLER LENFOSİT BASKIN HODGKİN LENFOMA TEDAVİSİ

Öz

Nodüler lenfosit baskın Hodgkin Lenfoma (NLBHL) nadir görülen bir Hodgkin Lenfoma alt tipidir. Genel olarak saldırgan bir seyir göstermeyen hastalık, sıklıkla periferal lenfadenomegaliler dışında asemptomatiktir. Hodgkin Lenfoma gibi Cots-Wolds modifikasyonuyla Ann-Arbor evreleme sistemine göre evrelenir. Tedavide kemoterapi ve radyoterapi ya da bunların kombinasyonları kullanılabilir. Bu derlemede NLBHL'nin çalışmalar eşliğinde tedavisinden bahsedeceğiz.

Anahtar Kelimeler

• Nodüler Lenfosit Predominant Hodgkin Lenfoma

Öz

Nodular lymphocyte predominate Hodgkin Lymphoma (NLPHL) is a rare subtype of Hodgkin Lymphoma. Disease is generally nonaggressive and asymptomatic except peripheral lymphadenomegaly. Cots-Wolds modified Ann Arborsystem is used for staging. Treatment of NLPHL consists of chemotherapy, radiotherapy or combination of both. We will discuss the treatment of the disease in the light of the literature.

Anahtar Kelimeler

• Noduler Lymphocyte Predominate Hodgkin Lymphoma

Kaynakça

1. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265.
2. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe bymorphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724.
3. Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed Sternbergcells in lymphocyte predominant Hodgkin diseasere present clonal populations of germinal center- derived tumor B cells. ProcNatl Acad Sci USA. 1997;94:9337. 4. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin'sdisease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453.
4. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med. 1997;337:459
5. Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151.
6. Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993;71:2062.
7. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the EuropeanTask Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17:776.
8. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Grouptrials. J ClinOncol. 2005;23:5739.

9. National Comprehensive Cancer Network (NCCN 2.2015). NCCN
10. http://www.nccn.org/professionals/physician_gls/f_guidelines. asp
11. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte- predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28:136.
12. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221.
13. Nogová L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte- predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16:1683.
14. Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancerand Groupe d'Etudedes Lymphomes de l'Adultevery favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002;94:1731.
15. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior toradiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J ClinOncol. 2007;25:3495.
16. Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancerand Leukaemia Groupreport. Br J Haematol. 2007;138:761.
17. Fanale MA, Lai CM, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:2812.
18. Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J ClinOncol. 1997;15:3060.
19. Karuturi M, Hosing C, Fanale M, et al. High- dosechemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013;19:991. in
20. oncology. 11. 12. 13. 14. 15. 16. 17. 18. 19. http://edergi.cbu.edu.tr/ojs/index.php/cbusbed isimli
21. yazarın CBU-SBED başlıklı eseri bu Creative Commons Alıntı-Gayriticari lisanslanmıştır. Lisansı ile